[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337482-105":59,"doc-detail-337482-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","upregulation-of-cald1-predicted-a-poor-prognosis-for-platinum-treated-ovarian-cancer","Upregulation of CALD1 - predicted a poor prognosis for platinum-treated ovarian cancer","","Ovarian cancer has the worst prognosis among gynecologic malignancies, and platinum-based chemotherapy is limited by relapse and drug resistance. This study screened and evaluated CALD1 as a molecular target linked to cisplatin resistance. Protein expression patterns were assessed across multiple public datasets, including GEO, TCGA, CCLE, and HPA. Clinical analyses used survival curves and ROC/AUC metrics to test prognostic and diagnostic performance, supporting CALD1 as a candidate therapeutic resistance marker.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/upregulation-of-cald1-predicted-a-poor-prognosis-for-platinum-treated-ovarian-cancer/337482/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/upregulation-of-cald1-predicted-a-poor-prognosis-for-platinum-treated-ovarian-cancer/337482.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What medical problem does the study address?","Question",{"text":112,"@type":113},"It targets the molecular basis of platinum chemotherapy resistance in ovarian cancer, which leads to relapse and poor outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CALD1 evaluated in relation to prognosis and diagnosis?",{"text":117,"@type":113},"The study assessed CALD1 using survival curve analysis for platinum-treated patients and used ROC curve analysis on clinical samples to evaluate diagnostic discrimination.",{"name":119,"@type":110,"acceptedAnswer":120},"Which data sources and analyses were used to support CALD1 as a candidate target?",{"text":121,"@type":113},"It integrated results from multiple databases and analytic tools, including GEO, TCGA, CCLE, HPA, GEPIA 2, UALCAN, Kaplan–Meier plotter, LinkedOmics, and String, and analyzed differential expression across cisplatin-sensitive versus -resistant datasets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337482,1790182600,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Li etal. BMC Genomics (2024) 25:183 [https://doi.org/10.1186/s12864-024-10056-0](https://doi.org/10.1186/s12864-024-10056-0)  \nBMC Genomics  \n RESEARCH Open Access  \nUpregulation of CALD1  \npredicted a poor  \nprognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target  \nWei Li1, Limei Huang1, Nana Qi1, Qinle Zhang1* and Zailong Qin1*  \nAbstract  \nBackground Ovarian cancer (OC) has the worst prognosis among gynecological malignancies, most of which are found to be in advanced stage. Cell reduction surgery based on platinum-based chemotherapy is the current standard of treatment for OC, but patients are prone to relapse and develop drug resistance. The objective of this study was to identify a specific molecular target responsible for platinum chemotherapy resistance in OC.  \nResults We screened the protein-coding gene Caldesmon (CALD1), expressed in cisplatin-resistant OC cells in vitro. The prognostic value of CALD1 was evaluated using survival curve analysis in OC patients treated with platinum therapy. The diagnostic value of CALD1 was verified by drawing a Receiver Operating Characteristic (ROC) curve using clinical samples from OC patients. This study analyzed data from various databases including Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), The Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), GEPIA 2, UALCAN, Kaplan–Meier (KM) plotter, LinkedOmics database, and String. Different expression genes (DEGs) between cisplatin-sensitive and cisplatin-resistant cells were acquired respectively from 5 different datasets of GEO. CALD1 was selected as a common gene from 5 groups DEGs. Online data analysis of HPA and CCLE showed that CALD1 was highly expressed in both normal ovarian tissue and OC. In TCGA database, high expression of CALD1 was associated with disease stage and venous invasion in OC. Patients with high CALD1 expression levels had a worse prognosis under platinum drug intervention, according to Kaplan–Meier (KM) plotter analysis. Analysis of clinical sample data from GEO showed that CALD1 had superior diagnostic value in distinguishing patients with platinum \"resistant\" and platinum \"sensitive\" (AUC = 0 . 816), as well as patients with worse progression-free survival (AUC = 0 . 741), and those with primary and omental metastases (AUC = 0 . 811) in ovarian tumor. At last, CYR61 was identified  \nas a potential predictive molecule that may play an important role alongside CALD1 in the development of platinum resistance in OC.  \nConclusions CALD1, as a member of cytoskeletal protein, was associated with poor prognosis of platinum resistance in OC, and could be used as a target protein for mechanism study of platinum resistance in OC.  \nKeywords CALD1, Ovarian cancer, Platinum resistance, Prognosis value, Target  \n*Correspondence:  \nQinle Zhang [qinlezhang@hotmail.com](qinlezhang@hotmail.com)[ ](qinlezhang@hotmail.com)Zailong Qin [qinzailong@163.com](qinzailong@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.","cbCaihZGRRNWWlWG","https://ap.wps.com/l/cbCaihZGRRNWWlWG","pdf",8885310,23,"English","# Abstract\n## Background\n## Results\n## Conclusions\n# Background","[{\"question\":\"What medical problem does the study address?\",\"answer\":\"It targets the molecular basis of platinum chemotherapy resistance in ovarian cancer, which leads to relapse and poor outcomes.\"},{\"question\":\"How was CALD1 evaluated in relation to prognosis and diagnosis?\",\"answer\":\"The study assessed CALD1 using survival curve analysis for platinum-treated patients and used ROC curve analysis on clinical samples to evaluate diagnostic discrimination.\"},{\"question\":\"Which data sources and analyses were used to support CALD1 as a candidate target?\",\"answer\":\"It integrated results from multiple databases and analytic tools, including GEO, TCGA, CCLE, HPA, GEPIA 2, UALCAN, Kaplan–Meier plotter, LinkedOmics, and String, and analyzed differential expression across cisplatin-sensitive versus -resistant datasets.\"}]","Upregulation of CALD1 - predicted a poor prognosis for platinum-treated ovarian cancer | PDF",1790019314,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f2f75668a5a07cdcf4900fde2bbdebb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dee2769257d29ea9410a046e9f069d54.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a50233c897c0d628c41803fd4f216ecc.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa4d7951c05aa45050afebcdd11f66b6.webp",980,1301]